Aytu BioPharma, Inc.
AYTU Healthcare Drug Manufacturers Specialty & Generic
Aytu BioPharma, Inc.’s revenue for fiscal 2026 (year ended June 2026) was $57.6 million, down 13.3% from fiscal 2025. In the quarter to June 2026, revenue grew 6.42%, EPS grew 100.0%, free cash flow grew 57.7% and total debt fell 21.9%, each against the same quarter a year earlier.
Follow AYTU
Aytu BioPharma, Inc. (AYTU) Piotroski F-score
Aytu BioPharma, Inc.'s Piotroski F-score for fiscal 2026 is 3 out of 9: 3 of nine tests of profitability, leverage and efficiency passed, down from 4 in fiscal 2025.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2026 | 3 | (1.00) |
| FY2025 | 4 | 1.00 |
| FY2024 | 3 | (2.00) |
| FY2023 | 5 | 2.00 |
| FY2022 | 3 | 0.00 |
| FY2021 | 3 | 0.00 |
| FY2020 | 3 | (2.00) |
| FY2019 | 5 | 1.00 |
| FY2018 | 4 | — |
How fiscal 2026’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (12.44%) | (11.20%) | Fail | 0 |
| Positive operating cash flow | 3.28m | (1.94m) | Pass | 1 |
| Rising return on assets | (12.44%) | (11.20%) | Fail | 0 |
| Cash flow above net income | 17.53m | 11.63m | Pass | 1 |
| Falling long-term leverage | 0.08 | 0.09 | Pass | 1 |
| Rising current ratio | 1.13 | 1.26 | Fail | 0 |
| No new shares issued | 12,320,000 | 6,280,000 | Fail | 0 |
| Rising gross margin | 63.95% | 69.04% | Fail | 0 |
| Rising asset turnover | 0.50 | 0.55 | Fail | 0 |
| Piotroski F-score | Weak — most fundamentals deteriorated | 3 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| TXMD TherapeuticsMD, Inc. compare | 6 |
| CPHI China Pharma Holdings, Inc. compare | 5 |
| UPC Universe Pharmaceuticals INC compare | 4 |
| BFRI Biofrontera Inc. compare | 3 |
| IXHL Incannex Healthcare Inc. compare | 3 |
| AYTU Aytu BioPharma, Inc. | 3 |
| RMTI Rockwell Medical, Inc. compare | 3 |
| SHPH Shuttle Pharmaceuticals Holdings, Inc. compare | — |
| BGXXQ Bright Green Corporation compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover